Institution
Incyte
Company•Wilmington, Delaware, United States•
About: Incyte is a company organization based out in Wilmington, Delaware, United States. It is known for research contribution in the topics: Expression vector & Ruxolitinib. The organization has 1262 authors who have published 1875 publications receiving 75015 citations. The organization is also known as: Incyte Corporation & Incyte Inc..
Topics: Expression vector, Ruxolitinib, Cancer, Polynucleotide, Antibody
Papers published on a yearly basis
Papers
More filters
Patent•
13 Nov 2008TL;DR: In this paper, substituted bicyclic heteroaryl compounds, including 4-pyrazolyl-N-arylpyrimidin-2-amines, were used to modulate the activity of kinases.
Abstract: The present invention provides substituted bicyclic heteroaryl compounds, including, for example, 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines that modulate the activity of kinases and are useful in the treatment of diseases related to activity of kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
72 citations
TL;DR: Preliminary P1/2 safety and tolerability outcomes for the overall study population and P2 response for select tumor types are reported and preliminary DCR (CR+PR+SD) is presented.
Abstract: 3003Background: ECHO-204 is an ongoing, open-label, phase 1/2 (P1/2) study of epacadostat (E; potent and selective oral inhibitor of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1) plus PD-1 inhibitor nivolumab (N) in patients (pts) with advanced cancers (NSCLC, MEL, OVC, CRC, SCCHN, B-cell NHL [including DLBCL], GBM). Preliminary P1/2 safety and tolerability outcomes for the overall study population and P2 response for select tumor types (SCCHN, MEL, OVC, CRC) are reported. Methods: In P1 dose escalation, pts received E (25, 50, 100, 300 mg BID) + N (3 mg/kg Q2W); in P2 cohort expansion, pts received E (100 or 300 mg BID) + N (240 mg Q2W). Safety/tolerability was assessed in pts receiving ≥1 E + N dose. Response was assessed in RECIST v1.1 evaluable pts; for recently enrolled pt subgroups, only preliminary DCR (CR+PR+SD) is presented. Results: As of 29OCT2016,241 pts (P1, n = 36; P2, n = 205) were enrolled. No DLT was observed in P1. Most common TRAEs (≥15%) in pts treated with E 100 mg (n = ...
72 citations
Patent•
30 Jan 1998TL;DR: In this paper, a plurality of polynucleotide probes can be used as array elements in a microarray, and a method for selecting polynotide probes of the composition can also be found.
Abstract: The present invention relates to a composition comprising a plurality of polynucleotide probes. The composition can be used as array elements in a microarray. The present invention also relates to a method for selecting polynucleotide probes of the composition.
72 citations
TL;DR: These findings are the first to directly demonstrate that ADAM17 cleaves CD16 in human leukocytes and show that this mechanism cannot be modeled in normal mice.
71 citations
Patent•
23 Apr 2009TL;DR: In this article, the authors defined macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ ALK inhibitors useful in the treatment of JAK and ALKassociated diseases including, for example, inflammatory and autoimmune disorders.
Abstract: The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
71 citations
Authors
Showing all 1267 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Patrick O. Brown | 183 | 755 | 200985 |
| David Botstein | 165 | 468 | 212787 |
| Inês Barroso | 113 | 301 | 76241 |
| Alessandro M. Vannucchi | 94 | 715 | 35482 |
| Ana M. Valdes | 84 | 334 | 26627 |
| Mark C. Genovese | 79 | 364 | 26945 |
| Michael B. Eisen | 71 | 170 | 89150 |
| Jingyue Ju | 61 | 169 | 18952 |
| Jeanne F. Loring | 60 | 177 | 14503 |
| James Z. Wang | 57 | 225 | 21890 |
| Emmett V. Schmidt | 50 | 150 | 9304 |
| Günther Sperk | 50 | 124 | 10246 |
| Robert C. Newton | 44 | 111 | 7369 |
| Magnus Pfahl | 44 | 87 | 8064 |
| William V. Williams | 44 | 168 | 7278 |